---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-175601"
form_type: "8-K/A"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2022-06-16T23:59:59+00:00"
generated_at: "2026-06-25T01:17:34.972769+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cogent closes upsized $172.6M public offering of common stock and pre-funded warrants

## Summary
- Gross proceeds ~$172.6M from 17,899,698 shares at $8.25 and 3,030,302 pre-funded warrants at $8.24.
- Net proceeds to fund development and commercial activities for bezuclastinib and other candidates.
- Underwriters exercised in full their option to purchase 2,730,000 additional shares.
- Pre-funded warrants exercisable at $0.01 per share, subject to 9.99% beneficial ownership limitation.

## SEC filing metadata
- accession: 0001193125-22-175601
- form_type: 8-K/A
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2022-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312522175601/0001193125-22-175601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312522175601/d357403d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-175601
- JSON: https://secwatch.observer/filing/0001193125-22-175601.json
- Plain text: https://secwatch.observer/filing/0001193125-22-175601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.